Located in Jinan's Lixia Economic Development Area, the Lishan International Biopharmaceutical Production Base is fast becoming a driving force in China's biopharma industry. Developed by Lishan Health Group, a subsidiary of Lixia Holding Group, the 470,000-square-meter base integrates advanced R&D labs, GMP-certified manufacturing, and smart office spaces. Its strategic location places it at the center of Shandong province's 100 billion yuan (approximately $14 billion) healthcare cluster initiative.

Lixia district offers a unique scientific ecosystem, anchored by 21 medical universities, including Cheeloo College of Medicine, Shandong University, 11 top-tier hospitals, and over 100 research institutes. This concentration supports robust collaboration between academia and industry, giving companies direct access to talent, research, and clinical resources.

The park's design blends innovation with practicality: low-density workspaces, column spans of 8.4 meters, and 7-meter-high lab ceilings meet the needs of advanced biomanufacturing. Modular spaces from 1,000 to 4,000 square meters support flexible layouts, while dual power systems and landscaped terraces enhance operational continuity and employee wellbeing.

Beyond infrastructure, the base fosters a collaborative ecosystem through shared research platforms, incubators, and partnerships in smart healthcare and elderly care. As part of the Healthy China 2030 vision, it is set to become a launchpad for next-generation therapies.

As Jinan rises as a biopharma hub, Lishan International welcomes innovators with scalable, policy-aligned growth opportunities in a thriving scientific environment.